Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
July, 2026
July 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Maciej Banach: Emerging Triglyceride Targeted Therapies in MASLD and Liver Disease
Maciej Banach/radcliffemedicaleducation.org; Seyed Saeed Tamehri Zadeh/LinkedIn; Peter P. Toth/primeinc.org
Apr 18, 2026, 12:22

Maciej Banach: Emerging Triglyceride Targeted Therapies in MASLD and Liver Disease

Maciej Banach, Vice-Rector for the Collegium Medicum at John Paul II Catholic University of Lublin, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Frontiers in Pharmacology Journal, adding:

“Please see our recent hot topic review on ‘Triglyceride-lowering therapies for hepatic steatosis’ just accepted for the Frontiers in Pharmacology journal with Seyed Saeed Tamehri Zadeh and Peter P. Toth.

Hepatic steatosis, the hallmark of MASLD, is closely associated with elevated plasma and intrahepatic triglyceride (TG) levels, often driven by insulin resistance, atherogenic dyslipidemia, and metabolic syndrome.

Growing evidence suggests that triglyceride-lowering therapies may not only improve systemic lipid profiles but also directly impact hepatic fat accumulation and associated inflammation and fibrosis.

This review explores current and emerging TG-lowering therapies, including fibrates, omega3 fatty acids, and novel agents such as pegozafermin (an FGF21 analog), and APOC3 and angiopoietin-like protein 3 (ANGPTL3) inhibitors, in the context of hepatic steatosis and MASLD.

We discuss the mechanistic rationale behind TG-lowering as a therapeutic strategy, summarize key preclinical and clinical trial findings, and evaluate their effects on liver fat content, liver enzymes, fibrosis markers, and histologic outcomes.

While several agents demonstrate promise in reducing intrahepatic fat deposition and improving liver-related outcomes, further large-scale studies are required to establish their long-term efficacy and safety, and potential for disease modification in MASLD/MASH.

Triglyceride-targeted therapies may offer a valuable adjunct or complementary approach to current treatment paradigms focused on weight loss, insulin sensitization, and antagonizing inflammation.

The preprint version is available․”

Title: Triglyceride-lowering therapies for hepatic steatosis: mechanisms, efficacy, and clinical perspectives

Author: Seyed Saeed Tamehri Zadeh, Peter Paul Toth, Maciej Banach

Maciej Banach: Emerging Triglyceride Targeted Therapies in MASLD and Liver Disease

Other posts featuring Maciej Banach on Hemostasis Today.

(inflammation Cardiology dyslipidemia Health Hematology Hemostasis Hemostasis News Hemostasis Today hepatic steatosis insulin resistance Maciej Banach MASH MASLD Medicine pegozafermin TG Triglyceride triglyceride-lowering therapies
NewsFeed